GleamWall
中文EN

EOLS Evolus, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1570562 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.1%
TTM net income YoY-16.5%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR28.0%
Net income 3-yr CAGR—

Margins

Gross margin67.2%
Operating margin-15.5%
Net margin-22.3%
FCF margin-15.5%
EBITDA margin-14.0%

Returns

ROE-18,729.6%
ROA-26.8%
ROIC (approx.)-61.1%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets108.2%
Debt / equity—
Current ratio2.27x
Interest coverage-2.06x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$77.95M$84.08M$73.14M$90.30M$68.97M$69.39M$68.52M$78.95M
Cost of revenue$27.27M$26.90M$24.24M$31.01M$23.13M$24.07M$21.87M$28.60M
Gross profit$50.69M$57.18M$48.90M$59.29M$45.84M$45.32M$46.66M$52.63M
R&D expense$1.97M$1.89M$2.24M$3.48M$2.05M$1.84M$2.21M$2.43M
SG&A expense$52.92M$57.05M$51.98M$54.66M$52.82M$56.67M$56.64M$50.24M
Operating income-$8.43M-$4.54M-$6.85M$4.22M-$11.50M-$10.21M-$15.17M-$2.31M
Interest expense$4.25M$4.17M$3.98M$3.98M$4.09M$7.21M$4.42M$4.57M
Pretax income-$12.23M-$8.21M-$10.42M$515,000-$15.57M-$17.09M-$18.82M-$6.35M
Income tax$285,000-$154,000$256,000$385,000$167,000$53,000$72,000$440,000
Net income-$12.52M-$8.05M-$10.67M$130,000-$15.74M-$17.14M-$18.89M-$6.79M
EBITDA-$6.85M-$3.01M-$4.50M$6.47M-$10.36M-$9.28M-$13.61M-$940,000
EPS (basic)-0.19-0.12-0.16—-0.24-0.27-0.30—
EPS (diluted)-0.19-0.12-0.16—-0.24-0.27-0.30—
Weighted avg. shares (diluted)66.09M65.93M65.19M—64.73M64.54M63.70M—
Balance sheet
Cash & equivalents$41.70M$45.17M$49.79M$53.83M$43.52M$61.74M$67.89M$86.95M
Receivables$60.28M$62.38M$52.22M$54.70M$50.44M$47.71M$47.45M$47.68M
Inventory$82.80M$40.90M$24.80M$26.96M$32.87M$26.46M$10.03M$12.16M
Current assets$201.74M$167.54M$138.92M$142.92M$134.89M$144.97M$131.72M$151.34M
PP&E, net$4.85M$5.05M$5.33M$5.37M$5.13M$3.65M$3.25M$3.22M
Goodwill$21.21M$21.21M$21.21M$21.21M$21.21M$21.21M$21.21M$21.21M
Intangibles$46.73M$45.69M$46.74M$48.04M$48.72M$49.35M$49.36M$48.75M
Total assets$283.82M$248.02M$220.65M$225.87M$219.00M$228.80M$213.36M$232.57M
Current liabilities$142.38M$98.73M$68.02M$75.31M$66.71M$63.75M$56.23M$62.96M
Long-term debt$156.90M$156.74M$156.41M$146.10M$145.78M$145.47M$121.81M$121.51M
Total debt$156.90M$156.74M$156.41M$146.10M$145.78M$145.47M$121.81M$121.51M
Total liabilities$321.64M$278.93M$249.43M$248.97M$247.76M$247.46M$219.97M$227.05M
Shareholders' equity-$37.81M-$30.90M-$28.78M-$23.11M-$28.76M-$18.65M-$6.60M$5.52M
Net debt$115.20M$111.57M$106.62M$92.27M$102.26M$83.74M$53.91M$34.55M
Shares outstanding66.14M66.01M65.84M65.01M64.77M64.64M64.45M63.50M
Cash flow statement
Operating cash flow-$1.93M-$3.59M-$9.95M$12.83M-$14.67M-$24.79M-$15.63M$4.81M
Capital expenditure$320,000$50,000$415,000$1.48M$955,000$688,000$319,000$438,000
Free cash flow-$2.25M-$3.64M-$10.37M$11.35M-$15.62M-$25.48M-$15.95M$4.37M
Investing cash flow-$1.81M-$500,000-$1.69M-$2.17M-$2.16M-$2.27M-$1.86M-$1.36M
Financing cash flow$101,000-$365,000$7.62M$77,000-$1.77M$20.66M-$1.63M-$1.31M
Depreciation & amortization$1.58M$1.53M$2.35M$2.25M$1.14M$932,000$1.56M$1.37M
Stock-based compensation$5.60M$5.62M$5.12M$5.15M$5.13M$4.49M$5.93M$6.17M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.